Investors
To find out more please contact info@highlighttherapeutics.com
Phase 2 asset BO-112 offers a unique and superior solution to anti PD1 resistance
Primary and acquired resistance a major barrier to successful cancer immunotherapy
Sound clinical strategy enabling Highlight to secure the first indication: 2L resistant melanoma
Marisol Quintero talks to Proactive London's Katie Pilbeam
Highlight Therapeutics Corporate Presentation
Highlight Therapeutics was founded in 2010 as a spin out of the Spanish National Cancer Center (CNIO) to commercially exploit the work of Damià Tormo and María Soengas.
It has raised more than €20 million since foundation, including an €11m Series A investment from DROIA Oncology Ventures in 2013.
It received a grant of more than €600,000 in 2016 from Spain’s Centre for the Development of Industrial Technology (CDTI) to support pre-clinical and clinical research into BO-112.
In 2019 we have received a public grant to support NOELIA´s project (Ensayo clínico fase I/II: nuevo enfoque terapéutico para el tratamiento de tumores sólidos con metástasis hepática) from the Spanish Ministerio de Ciencia e Innovación.
